U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Vaccines
  4. Cervarix
  1. Vaccines

STN:BL 125259
Proper Name:Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant
Tradename: Cervarix
Manufacturer: GlaxoSmithKline Biologicals
Indications:

  • Prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia (CIN) grade 1, caused by oncogenic human papillomavirus (HPV) types 16 and 18, in females 9 through 25 years of age

Product Information

Supporting Documents

Related Information

Back to Top